» Articles » PMID: 35220971

Implications of National Tax Policy on Local Pharmaceutical Production in a Southwestern State Nigeria - Qualitative Research for the Intersection of National Pharmaceutical Policy on Health Systems Development

Overview
Publisher Biomed Central
Specialty Health Services
Date 2022 Feb 28
PMID 35220971
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Universal access to quality and affordable medicines is one of the targets of the Sustainable Development Goals (SDGs). Access to essential medicines is defined as the availability of medicine at an affordable price in public and private health institutions including retail pharmacies in the proximity of less than an hour from the home of the population. The dependence on importation to meet the drug needs of an expanding population has implications on the growth of the local pharmaceutical industry, availability, and affordability of essential medicines in the country. This study aims to understand the dynamics of tariffs and tax policy on local drug production in the pharmaceutical industry in Nigeria.

Methods: This was a qualitative study involving the use of Key Informant Interviews (KIIs). A total of 15 stakeholders were interviewed. Interviews conducted were analysed thematically. The data generated were analysed using Atlas.Ti version 8.2.

Results: Assessment of the pharmaceutical industry sub-sector underscores myriads of challenges facing the industry and explains why the pharmaceutical industries in Nigeria are performing sub-optimally. Key stakeholders in the sector expressed concern about the fact that substantial percentage of drugs consumed in Nigeria are imported. Local manufacturers are underperforming due to several factors. Some highlighted factors were unfriendly tax environment, high cost of production, infrastructural deficit, low patronage from the government, and lack of access to low-interest rate loans. However, tax incentives and tax cuts are proven strategies to encourage and facilitate the growth of entrepreneurs in the pharmaceutical industry.

Conclusions: Stakeholders' perspective of implications of the tax environment on the pharmaceutical sector of Nigeria revealed the unfriendliness of the government policy to local manufacturers. Although the checklist for availability and prices of essential medicines in Osun state, Nigeria revealed that the pre-selected drugs were available in the facilities, the observed prices further affirmed the relative difficulty that is experienced by local manufacturers to compete with imported brands of the same drugs.

Citing Articles

The role of government in the achievement of medicines' security: A preliminary exploration of stakeholders' views and experience.

Adigwe O, Onavbavba G PLoS One. 2024; 19(6):e0299978.

PMID: 38848401 PMC: 11161072. DOI: 10.1371/journal.pone.0299978.


Promoting local production and active pharmaceutical ingredient (API) industry in low and middle income countries (LMICs): impact on medicines access and policy.

Abbas Khan M, Rauf A J Pharm Policy Pract. 2024; 17(1):2323683.

PMID: 38444526 PMC: 10913693. DOI: 10.1080/20523211.2024.2323683.


Cost and availability of selected medicines after implementation of increased import verification fees.

Ndagije H, Kesi D, Rajab K, Onen S, Serwanga A, Manirakiza L BMC Health Serv Res. 2024; 24(1):25.

PMID: 38178109 PMC: 10768383. DOI: 10.1186/s12913-023-10433-7.


Correction to: Implications of national tax policy on local pharmaceutical production in a southwestern state nigeria - qualitative research for the intersection of national pharmaceutical policy on health systems development.

Obembe T, Adenipekun A, Morakinyo O, Odebunmi K BMC Health Serv Res. 2022; 22(1):325.

PMID: 35272689 PMC: 8915524. DOI: 10.1186/s12913-022-07724-w.

References
1.
Niens L, Van de Poel E, Cameron A, Ewen M, Laing R, Brouwer W . Practical measurement of affordability: an application to medicines. Bull World Health Organ. 2012; 90(3):219-27. PMC: 3314216. DOI: 10.2471/BLT.10.084087. View

2.
Quick J . Essential medicines twenty-five years on: closing the access gap. Health Policy Plan. 2003; 18(1):1-3. DOI: 10.1093/heapol/18.1.1. View

3.
Knaul F, Arreola-Ornelas H, Mendez-Carniado O, Bryson-Cahn C, Barofsky J, Maguire R . Evidence is good for your health system: policy reform to remedy catastrophic and impoverishing health spending in Mexico. Lancet. 2006; 368(9549):1828-41. DOI: 10.1016/S0140-6736(06)69565-2. View

4.
Hogerzeil H . Essential medicines and human rights: what can they learn from each other?. Bull World Health Organ. 2006; 84(5):371-5. PMC: 2627335. DOI: 10.2471/blt.06.031153. View

5.
Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R . Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis. Lancet. 2008; 373(9659):240-9. DOI: 10.1016/S0140-6736(08)61762-6. View